These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 6997177)
21. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Rodríguez-Ortega MJ; Norais N; Bensi G; Liberatori S; Capo S; Mora M; Scarselli M; Doro F; Ferrari G; Garaguso I; Maggi T; Neumann A; Covre A; Telford JL; Grandi G Nat Biotechnol; 2006 Feb; 24(2):191-7. PubMed ID: 16415855 [TBL] [Abstract][Full Text] [Related]
22. Control of streptococcal infections. Priniciples and problems. Markowitz M Minn Med; 1975 Aug; 58(8):603-6. PubMed ID: 1152837 [No Abstract] [Full Text] [Related]
23. Immunity to group a streptococcal M proteins: forging a single-edged sword. Madoff LC Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630 [No Abstract] [Full Text] [Related]
24. Group A streptococcus epidemiology and vaccine implications. Cohen-Poradosu R; Kasper DL Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050 [No Abstract] [Full Text] [Related]
25. Progress toward a global group a streptococcal vaccine. Steer AC; Dale JB; Carapetis JR Pediatr Infect Dis J; 2013 Feb; 32(2):180-2. PubMed ID: 23328823 [No Abstract] [Full Text] [Related]
26. Progress in development of Group A Streptococcus vaccines. Song Y; Zhang X; Lu C; Zhang F; Zhu H Curr Pharm Biotechnol; 2013; 14(11):947-50. PubMed ID: 24372248 [TBL] [Abstract][Full Text] [Related]
27. Bacteria spurned by self-absorbed cells. Gorvel JP; de Chastellier C Nat Med; 2005 Jan; 11(1):18-9. PubMed ID: 15635436 [No Abstract] [Full Text] [Related]
28. Lipid core peptide technology and group A streptococcal vaccine delivery. Olive C; Batzloff MR; Toth I Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243 [TBL] [Abstract][Full Text] [Related]
29. Problems of erysipelas. 3. Streptococcal vaccine treatment of relapsing erysipelas. Korossy S; Rajka O; Böszörményi J; Gózony M Acta Med Acad Sci Hung; 1968; 25(1):51-61. PubMed ID: 5678738 [No Abstract] [Full Text] [Related]
30. The next chapter in reverse vaccinology. Musser JM Nat Biotechnol; 2006 Feb; 24(2):157-8. PubMed ID: 16465156 [No Abstract] [Full Text] [Related]
31. [Study of the active prophylaxis of streptococcal infections in experiments on monkeys]. Köhler W; Dzhikidze EK; Kühnemund O; Wagner M; Voskanian NA Vestn Akad Med Nauk SSSR; 1977; (8):52-9. PubMed ID: 410188 [No Abstract] [Full Text] [Related]
32. Streptococcal sore throat--status of the streptococcal vaccine. Kossmann CE J Tenn Med Assoc; 1981 Apr; 74(4):269-74, 276. PubMed ID: 7253646 [No Abstract] [Full Text] [Related]
33. [Reliability of the rapid Streptococcus A test]. Schmuziger N; Frei R; Hauser R; aWengen D; Probst R HNO; 1996 Jul; 44(7):365-9. PubMed ID: 8926181 [TBL] [Abstract][Full Text] [Related]
34. The inequitable burden of group A streptococcal diseases in Indigenous Australians. May PJ; Bowen AC; Carapetis JR Med J Aust; 2016 Sep; 205(5):201-3. PubMed ID: 27581260 [No Abstract] [Full Text] [Related]
35. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes. Schulze K; Olive C; Ebensen T; Guzmán CA Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529 [TBL] [Abstract][Full Text] [Related]
36. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. Shet A; Kaplan EL; Johnson DR; Cleary PP J Infect Dis; 2003 Sep; 188(6):809-17. PubMed ID: 12964111 [TBL] [Abstract][Full Text] [Related]
37. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice. Okamoto S; Tamura Y; Terao Y; Hamada S; Kawabata S Vaccine; 2005 Sep; 23(40):4852-9. PubMed ID: 15990202 [TBL] [Abstract][Full Text] [Related]